WIRED spoke with DeepMind’s Pushmeet Kohli about the recent past—and promising future—of the Nobel Prize-winning research ...

The study presents valuable findings of an optimized E. coli cell-free protein synthesis (eCFPS) system that has been simplified by reducing the number of core components from 35 to 7; furthermore, ...

mRNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the blueprint for functional proteins in the body and induces therapeutic effects.

Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B round of financing that will be used to expand the company’s DNA synthesis production capacity in the U.S. The San ...

When Health and Human Services Secretary Robert F. Kennedy Jr. terminated $500 million in federal funding for mRNA vaccine research last week, claiming he had “reviewed the science,” his press release ...

WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms through the Biomedical Advanced Research and Development Authority, the agency ...

According to Nova One Advisor, the U.S. mRNA synthesis raw materials market size is expected to be worth around 1,161.26 million by 2034, increasing from USD 893.13 million in 2025, representing a ...

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...

A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various ...